Saturday, 17 October 2026European Markets

HOTELS DE PARIS Stock Bearish Momentum With A 10% Drop So Far On Tuesday

Loading stream...

(vianews) - shares of hotels de paris (cac 40: hdp.pa) slid by a staggering 10.4% to €2.24 at 11:54 est on tuesday, after two consecutive sessions in a row of gains. cac 40 is rising 0.67% to €7,191.35, after two consecutive sessions in a row of gains. this seems, up to now, a somewhat bullish trend trading session today.

about hotels de paris

les hôtels de paris sa operates and manages hotels in paris. as of december 31, 2021, it operated 17 hotels in paris, 1 hotel in st tropez, and 1 hotel in marrakech. the company was incorporated in 1992 and is headquartered in paris, france.

earnings per share

as for profitability, hotels de paris has a trailing twelve months eps of €-0.71.

volatility

hotels de paris's last week, last month's, and last quarter's current intraday variation average was 13.11%, 4.29%, and 6.10%.

hotels de paris's highest amplitude of average volatility was 13.11% (last week), 8.96% (last month), and 6.10% (last quarter).

more news about hotels de paris (hdp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com